Glycemic control as a part of coronary stenosis prevention strategy in type 2 diabetes patients before and after transcutaneous coronary intervention

Cover Page

Cite item

Full Text

Abstract

Diabetes mellitus type 2 (DM 2) is judgefully beleaved to be one of the most sufficient populational risk factors for cardiovascular diseases, and is supposed to be the predictor of unfavorable currence of previously diagnosed coronary heart disease (CAD). Increased cardiovascular hazard in DM 2 is realized due to such coronary atherosclerosis peculiarities as more extensive, multivessel lesion and a bigger stenosis degree. Modern percutaneous coronary intervention (PCI) facilities provide significant survival and quality of life improvement. But there are more frequent target lesion revascularization in DM 2 patients for restenosis. The article covers some questions concerning the influence of glycemic control in DM 2 on different features of CAD progression and in-stent restenosis development in DM 2 patients who underwent PCI. Different aspects of restenosis pathogenesis and prevention are illuminated.

About the authors

V. V Salukhov

S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation

Email: vlasaluk@yandex.ru
д-р мед. наук, нач. 1-й каф. (терапии усовершенствования врачей) ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6

S. V Kadin

S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation

канд. мед. наук, преподаватель 1-й каф. (терапии усовершенствования врачей) ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6

A. F Agliullin

S.M.Kirov Medical Military Academy of the Ministry of Defence of the Russian Federation

слушатель клин. ординатуры ФГБВОУ ВО им. С.М.Кирова 194044, Russian Federation, Saint Petersburg, ul. Akademika Lebedeva, d. 6

References

  1. Hurst R.T, Lee R.W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003; 139: 824-34.
  2. Kip K.E, Faxon D.P, Detre K.M et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation1996; 94: 1818-25.
  3. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
  4. Stamler J, Vaccaro O, Neaton J.D et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993; 16: 434-44.
  5. Alderman E.L, Corley S.D, Fisher L.D et al. Five - year angiographic follow - up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141-54.
  6. Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995; 75: 894-903.
  7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-53.
  8. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta - analysis of 102 prospective studies. Lancet 2010; 375 (9733): 2215-22.
  9. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-42.
  10. Wannamethee S.G, Shaper A.G, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004; 90: 1398-403.
  11. Fisher M. Diabetes: can we stop the time bomb? Heart 2003; 89 (Suppl. 2): 28-30.
  12. Акчурин Р.С., Власова Э.Е., Мершин К.В. Сахарный диабет и хирургическое лечение ишемической болезни сердца. Вестн. РАМН. 2012; 1: 14-9.
  13. Дедов И.И. Диабет как фактор риска сердечно - сосудистых заболеваний. Сердечная недостаточность. 2003; 3: 16-9.
  14. Soinio M, Marniemi J, Laakso M et al. High - sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes. A 7-year follow - up study. Diabetes Care 2006; 29 (2): 329-33.
  15. Торшхоева Х.Н., Ткачева О.Н., Подпругина Н.Г. и др. Диабетическая кардиоваскулярная автономная нейропатия. Сахарный диабет. 2004; 1: 38-9.
  16. Radermecker R.P, Philips J.C, Jandrain B et al. Blood glucose control and cardiovascular disease in patiens with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials. Rev Med Liege 2008; 63 (7-8): 511-8.
  17. Dluhy R.G, Mc Mahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358 (24): 2630-3.
  18. Le Roith D, Fonseca V, Vinik A. Metabolic memory in diabetes - focus on insulin. Diabetes Metab Res Rev 2005; 21 (2): 85-90.
  19. Mick M.J, Piedmonte M.R, Arnold A.M et al. Risk stratification for long - term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994; 24: 74-80.
  20. The BARI Investigators. The Final 10-Year Follow - Up Results From the BARI Randomized Trial. J Am Coll Cardiol 2007; 49: 1600-6.
  21. Mathew V, Gersh B.J, Williams B.A et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109: 476-80.
  22. West N.E, Ruygrok P.N, Disco C.M et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109: 867-73.
  23. Mazeika P, Prasad N, Bui S et al. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J 2003; 145: 1013-21.
  24. Holmes D.R Jr, Leon M.B, Moses J.W et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus - eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-40.
  25. Byrne R.A, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going. Eur Heart J 2015; 36 (47): 3320-31.
  26. Legrand V. Therapy insight: Diabetes and drug - eluting stents. Nat Clin Pract Cardiovasc Med 2007; 4: 143-50.
  27. Fröbert O, Lagerqvist B, Carlsson J et al. Differences in restenosis rate with different drug - eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009; 53 (18): 1660-7.
  28. Hong S.J, Kim M.H, Ahn T.H et al. Multiple predictors of coronary restenosis after drug - eluting stent implantation in patients with diabetes. Heart 2006; 92: 1119-24.
  29. Svedman C, Ekqvist S, Moller H et al. A correlation found between contact allergy to stent material and restenosis of the coronary arteries. Contact Dermatitis 2009; 60: 158-64.
  30. Березовская Г.А., Ганюков В.И., Карпенко М.А. Рестеноз и тромбоз внутри стента: патогенетические механизмы развития и прогностические маркеры. Рос. кардиол. журн. 2012; 6 (98): 91-5.
  31. Tian F, Chen Y, Liu H et al. Assessment of characteristics of neointimal hyperplasia after drug - eluting stent implantation in patients with diabetes mellitus: an optical coherence tomography analysis. Cardiology 2014; 128 (1): 34-40.
  32. Ломоносова А.А., Григорова С.Ю., Афанасьев Ю.И. Проблема рестеноза после чрескожных внутрикоронарных вмешательств и перспективы его профилактики с помощью генотерапевтических воздействий. Науч. ведомости. 2010; 4 (75; Вып. 9).
  33. Aronson D, Bloomgarden Z, Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996; 27: 528-35.
  34. Kereiakes D.J, Young J.J. Percutaneous coronary revascularization of diabetic patients in the era of drug - eluting stents. Rev Cardiovasc Med 2005; 6 (Suppl. 1): S48-58.
  35. Beckman J.A, Creager M.A, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
  36. Sobel B.E. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99: 2496-8.
  37. Yusuf S, Zhao F, Mehta S.R et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
  38. Choi D, Kim S.K, Choi S.H et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-60.
  39. Dibra A, Kastrati A, Mehilli J et al. Paclitaxel - eluting or sirolimus - eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-70.
  40. Corpus R.A, George P.B, House J.A et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43: 8-14.
  41. Волкова Е.А., Ворохобина Н.В., Малыгина О.Ф. Модификация образа жизни, обучение и самоконтроль - важные компоненты лечения сахарного диабета и улучшения качества жизни пациентов. // Consilium Medicum. 2015; 17 (1): 54-62.
  42. Caswell M, Frank J, Viggiani M.T et al. Accuracy and user performance evaluation of a blood glucose monitoring system. Diabetes Technol Ther 2015; 17 (3): 152-8.
  43. Редькин Ю.А., Богомолов В.В., Древаль А.В. Влияние различных факторов на эффективность самоконтроля при сахарном диабете. // Consilium Medicum. 2011; 13 (12): 54-7.
  44. Dunne N, Viggiani M.T, Pardo S et al. Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems. Diabetes Ther 2015; 6 (3): 377-88.
  45. Аметов А.С., Черникова Н.А. Гликемический контроль у пациентов с сахарным диабетом типа 2. // Consilium Medicum. 2016; 18 (4): 24-7.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies